Institut Català d'Oncologia (ICO) - L'Hospitalet /ID# 262118

L'Hospitalet de Llobregat, Barcelona 08907

1 studies enrolling now · 1 studies all time

What they study most

Non-Small Cell Lung Cancer

Studies at this site

• Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) — Recruiting now